NasdaqGM - Nasdaq Real Time Price USD

CureVac N.V. (CVAC)

Compare

4.2100

-0.0200

(-0.47%)

At close: January 10 at 4:00:01 PM EST

4.4200

+0.21

+(4.99%)

After hours: 7:49:21 PM EST

Moderna stock forfeits gains as first US bird flu death puts vaccine development in focus

The first human bird flu death in the US has Moderna's vaccine development in focus for investors this week.

Yahoo Finance 2 days ago

PFE

CVAC
-0.47%
MRNA
Vaccine Stocks Jump After CDC Reports First US Bird-Flu Death

The first bird-flu fatality in the United States sparks investor interest in several vaccine makers that are developing experimental H5N1 vaccines.

Zacks 2 days ago

NVAX
-3.02%
MRNA

CVAC
-0.47%
Moderna Stock Jumps Amid Bird Flu Vaccine Hope After First U.S. Death

The company is one of a few drugmakers currently developing a vaccine for the illness, which is spreading rapidly through North America.

Barrons.com 3 days ago

MRNA

PFE

CVAC
-0.47%
Discover 3 US Penny Stocks With Market Caps Over $200M

As the U.S. stock market experiences a mixed performance, with the Dow Jones Industrial Average gaining for its fifth straight session while other indices falter, investors are exploring diverse opportunities. Penny stocks, often considered speculative investments due to their low price point and smaller market presence, can still offer significant potential when backed by strong financials. In this article, we will explore several penny stocks that stand out for their financial strength and...

Simply Wall St. 14 days ago

CVAC
-0.47%
SFIX

ZVIA
Cerus And 2 Other US Penny Stocks To Watch

The U.S. stock market recently experienced a stumble, particularly in technology shares, as investors assessed earnings reports and economic data amidst fluctuating interest rates and inflation expectations. In such a climate, the appeal of penny stocks remains significant for those seeking affordable entry points with potential growth prospects. While the term "penny stocks" may seem outdated, these typically smaller or newer companies can offer unique opportunities when supported by strong...

Simply Wall St. last month

CERS

CVAC
-0.47%
CLOV
Loss-Making CureVac N.V. (NASDAQ:CVAC) Set To Breakeven

CureVac N.V. ( NASDAQ:CVAC ) is possibly approaching a major achievement in its business, so we would like to shine...

Simply Wall St. last month

CVAC
-0.47%
Is the Options Market Predicting a Spike in CureVac (CVAC) Stock?

Investors need to pay close attention to CureVac (CVAC) stock based on the movements in the options market lately.

Zacks last month

CVAC
-0.47%
Is CureVac N.V. (CVAC) the Best German Stock to Buy Now?

We recently compiled a list of the 10 Best German Stocks To Buy Now. In this article, we are going to take a look at where CureVac N.V. (NASDAQ:CVAC) stands against the other German stocks. In Germany, the economic growth is based on industry. According to Deutschland.de, Germany’s manufacturing industry contributed 26.6% to the country’s gross […]

Insider Monkey last month

CVAC
-0.47%
Where are they now? 4 biotechs that soared then crashed during the pandemic

How Novavax and others have restructured and trudged forward after their COVID-era high.

Pharma Voice last month

CVAC
-0.47%
NVAX
-3.02%
INO
-5.26%
CureVac NV (CVAC) Q3 2024 Earnings Call Highlights: Strong Financial Performance and Strategic ...

CureVac NV (CVAC) reports robust revenue growth and strategic advancements in oncology, despite ongoing litigation challenges.

GuruFocus.com last month

CVAC
-0.47%
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update

Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter €400 million upfront payment from restructured GSK collaboration reflected in financials, cash position increased to €551 million; expected cash runway re-affirmed ...

ACCESSWIRE last month

CVAC
-0.47%
CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 7, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report ...

ACCESSWIRE 2 months ago

CVAC
-0.47%
CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer

Experienced CFO and investment banker with 30-year track record will help drive CureVac's transformation TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 4, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company ...

ACCESSWIRE 2 months ago

CVAC
-0.47%
CureVac to Present at the 12th International mRNA Health Conference

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 4, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced ...

ACCESSWIRE 2 months ago

CVAC
-0.47%
US Penny Stocks To Watch In October 2024

As the U.S. stock market continues its upward trajectory with major indices like the Nasdaq hitting record highs, investors are keenly analyzing corporate earnings and economic data to gauge future opportunities. In this context, penny stocks—often representing smaller or newer companies—remain an intriguing area for those looking beyond established giants. Despite their name suggesting a bygone era, these stocks can offer significant potential when backed by strong financials and strategic...

Simply Wall St. 2 months ago

CVAC
-0.47%
GLYC

HNST
GSK Cuts Vaccine Sales Outlook Amid U.S. Weakness

GSK cut its full-year vaccine sales outlook after key shots for respiratory syncytial virus and shingles missed expectations in the third quarter due to weak U.S. demand.

The Wall Street Journal 2 months ago

CVAC
-0.47%
GLAXF

GSK
CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / October 28, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced ...

ACCESSWIRE 2 months ago

CVAC
-0.47%
Pfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patents

LONDON (Reuters) -Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's High Court. Pfizer and BioNTech had filed their lawsuit in September 2022 over patents relating to messenger RNA (mRNA) technology, which underpins Pfizer and BioNTech's COVID-19 vaccine.

Reuters 3 months ago

PFE

BNTX
+0.57%
CVAC
-0.47%
CureVac N.V.'s (NASDAQ:CVAC) top owners are individual investors with 35% stake, while 31% is held by private equity firms

Key Insights CureVac's significant individual investors ownership suggests that the key decisions are influenced by...

Simply Wall St. 3 months ago

CVAC
-0.47%
CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress

Preliminary immunogenicity results demonstrate induction of cancer antigen-specific T-cell responses in 77% of evaluable patients following CVGBM monotherapy 84% of immune responses were de novo, observed in patients without pre-existingT-cell activity ...

ACCESSWIRE 3 months ago

CVAC
-0.47%

Performance Overview

Return	CVAC	S&P 500
YTD	+34.94%	-1.35%
1-Year	+5.51%	+22.51%
3-Year	-86.28%	+24.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

CureVac N.V. (CVAC)

Moderna stock forfeits gains as first US bird flu death puts vaccine development in focus

Vaccine Stocks Jump After CDC Reports First US Bird-Flu Death

Moderna Stock Jumps Amid Bird Flu Vaccine Hope After First U.S. Death

Discover 3 US Penny Stocks With Market Caps Over $200M

Cerus And 2 Other US Penny Stocks To Watch

Loss-Making CureVac N.V. (NASDAQ:CVAC) Set To Breakeven

Is the Options Market Predicting a Spike in CureVac (CVAC) Stock?

Is CureVac N.V. (CVAC) the Best German Stock to Buy Now?

Where are they now? 4 biotechs that soared then crashed during the pandemic

CureVac NV (CVAC) Q3 2024 Earnings Call Highlights: Strong Financial Performance and Strategic ...

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update

CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024

CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer

CureVac to Present at the 12th International mRNA Health Conference

US Penny Stocks To Watch In October 2024

GSK Cuts Vaccine Sales Outlook Amid U.S. Weakness

CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Pfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patents

CureVac N.V.'s (NASDAQ:CVAC) top owners are individual investors with 35% stake, while 31% is held by private equity firms

CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress

Performance Overview